Market Overview:
The global disruptive behavior disorders (DBD) market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of DBDs, rising awareness about DBDs and their treatment options, and growing demand for better treatment outcomes. Based on type, the global disruptive behavior disorders (DBD) market is segmented into stimulants and non-stimulants. The stimulants segment is further sub-segmented into amphetamines, methylphenidate hydrochloride (MPH), dextroamphetamine sulfate (Dexedrine), lisdexamfetamine dimesylate (Vyvanse), and others. The non-stimulants segment is further sub-segmented into atypical antipsychotics, serotonin norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), anticonvulsants/mood stabilizers, and others. Based on application, the global disruptive behavior disorders market is divided into conduct disorder and oppositional defiant disorder segments.
 Industry Outlook.svg)
Product Definition:
DBD is a classification of psychiatric disorders characterized by recurrent, impairing behavioral symptoms that significantly interfere with academic or occupational functioning or with the development and maintenance of social relationships.
Stimulants:
Stimulants are drugs that increase the body's ability to respond to a particular stimulus. They are used in various treatments such as for attention deficit hyperactivity disorder (ADHD), narcolepsy, and Parkinson's disease. Stimulants have been studied extensively due to their effectiveness in treating ADHD; they help improve focus and attention span, decrease restlessness or fidgeting, reduce impulsiveness, and improve mental alertness.
Non-stimulants:
Non-stimulants are drugs that produce minimal activation in the brain. They block or reduce the excitability of a part of the brain, which is responsible for symptoms related to Parkinson's disease, epilepsy, and schizophrenia. The most commonly used non-stimulant drug class is benzodiazepines; these include diazepam (Valium), alpidem (Lunarib), and lormetazepam ( hourly dose).
Application Insights:
Based on application, the global market is segmented into conduct disorder (CD), oppositional defiant disorder (ODD) and Attention Deficit Hyperactivity Disorder (ADHD). In 2017, the CD segment dominated the market with a share of over 60.0% in terms of revenue. Conduct disorders are characterized by early onset of antisocial behavior and failure to develop appropriate social skills. These disorders often occur along with other mental illnesses such as depression or anxiety which increases treatment needs.
The ODD segment is expected to witness significant growth during the forecast period owing to rising awareness about effective management of disruptive behavior among parents and educators across various regions especially in North America.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing awareness about mental health, availability of effective treatment methods, and supportive government initiatives. Moreover, rising prevalence of CD and ODD among children and adolescents in U.S., Canada, and Mexico is contributing toward regional growth.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure; growing economy; rising disposable income levels; expanding middle-class population base with higher spending capacity; changing demographics (age structure); urbanization trends; increased foreign direct investments (FDI) from developed economies including Japan & Australia.
Growth Factors:
- Increasing awareness about DBDs among people and healthcare professionals
- Rising incidence of DBDs across the globe
- Growing number of research studies on DBDs
- Availability of effective treatments for DBDs
- increasing funding for research on DBD
Scope Of The Report
Report Attributes
Report Details
Report Title
Disruptive Behavior Disorders (DBD) Market Research Report
By Type
Stimulants, Non-stimulants
By Application
Conduct Disorder (CD), Oppositional Defiant Disorder (ODD)
By Companies
Eli Lilly, Bionomics, Chelsea Therapeutics, Pfizer, Johnson & Johnson, DURECT, Novartis, McNeil Pharmaceuticals, Sunovion Pharmaceuticals, New River Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Disruptive Behavior Disorders (DBD) Market Report Segments:
The global Disruptive Behavior Disorders (DBD) market is segmented on the basis of:
Types
Stimulants, Non-stimulants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Conduct Disorder (CD), Oppositional Defiant Disorder (ODD)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Bionomics
- Chelsea Therapeutics
- Pfizer
- Johnson & Johnson
- DURECT
- Novartis
- McNeil Pharmaceuticals
- Sunovion Pharmaceuticals
- New River Pharmaceuticals
 Market Overview.svg)
Highlights of The Disruptive Behavior Disorders (DBD) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Stimulants
- Non-stimulants
- By Application:
- Conduct Disorder (CD)
- Oppositional Defiant Disorder (ODD)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Disruptive Behavior Disorders (DBD) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Disruptive behavior disorders (DBD) are a group of mental health conditions that include Attention Deficit Hyperactivity Disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder. These conditions are characterized by problems with attention, hyperactivity, and impulsiveness. They can interfere with normal life activities and relationships.
Some of the key players operating in the disruptive behavior disorders (dbd) market are Eli Lilly, Bionomics, Chelsea Therapeutics, Pfizer, Johnson & Johnson, DURECT, Novartis, McNeil Pharmaceuticals, Sunovion Pharmaceuticals, New River Pharmaceuticals.
The disruptive behavior disorders (dbd) market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Disruptive Behavior Disorders (DBD) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Disruptive Behavior Disorders (DBD) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Disruptive Behavior Disorders (DBD) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Disruptive Behavior Disorders (DBD) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Disruptive Behavior Disorders (DBD) Market Size & Forecast, 2018-2028
4.5.1 Disruptive Behavior Disorders (DBD) Market Size and Y-o-Y Growth
4.5.2 Disruptive Behavior Disorders (DBD) Market Absolute $ Opportunity
Chapter 5 Global Disruptive Behavior Disorders (DBD) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Disruptive Behavior Disorders (DBD) Market Size Forecast by Type
5.2.1 Stimulants
5.2.2 Non-stimulants
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Disruptive Behavior Disorders (DBD) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Disruptive Behavior Disorders (DBD) Market Size Forecast by Applications
6.2.1 Conduct Disorder (CD)
6.2.2 Oppositional Defiant Disorder (ODD)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Disruptive Behavior Disorders (DBD) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Disruptive Behavior Disorders (DBD) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Disruptive Behavior Disorders (DBD) Analysis and Forecast
9.1 Introduction
9.2 North America Disruptive Behavior Disorders (DBD) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Disruptive Behavior Disorders (DBD) Market Size Forecast by Type
9.6.1 Stimulants
9.6.2 Non-stimulants
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Disruptive Behavior Disorders (DBD) Market Size Forecast by Applications
9.10.1 Conduct Disorder (CD)
9.10.2 Oppositional Defiant Disorder (ODD)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Disruptive Behavior Disorders (DBD) Analysis and Forecast
10.1 Introduction
10.2 Europe Disruptive Behavior Disorders (DBD) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Disruptive Behavior Disorders (DBD) Market Size Forecast by Type
10.6.1 Stimulants
10.6.2 Non-stimulants
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Disruptive Behavior Disorders (DBD) Market Size Forecast by Applications
10.10.1 Conduct Disorder (CD)
10.10.2 Oppositional Defiant Disorder (ODD)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Disruptive Behavior Disorders (DBD) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Disruptive Behavior Disorders (DBD) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Disruptive Behavior Disorders (DBD) Market Size Forecast by Type
11.6.1 Stimulants
11.6.2 Non-stimulants
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Disruptive Behavior Disorders (DBD) Market Size Forecast by Applications
11.10.1 Conduct Disorder (CD)
11.10.2 Oppositional Defiant Disorder (ODD)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Disruptive Behavior Disorders (DBD) Analysis and Forecast
12.1 Introduction
12.2 Latin America Disruptive Behavior Disorders (DBD) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Disruptive Behavior Disorders (DBD) Market Size Forecast by Type
12.6.1 Stimulants
12.6.2 Non-stimulants
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Disruptive Behavior Disorders (DBD) Market Size Forecast by Applications
12.10.1 Conduct Disorder (CD)
12.10.2 Oppositional Defiant Disorder (ODD)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Disruptive Behavior Disorders (DBD) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Disruptive Behavior Disorders (DBD) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Disruptive Behavior Disorders (DBD) Market Size Forecast by Type
13.6.1 Stimulants
13.6.2 Non-stimulants
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Disruptive Behavior Disorders (DBD) Market Size Forecast by Applications
13.10.1 Conduct Disorder (CD)
13.10.2 Oppositional Defiant Disorder (ODD)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Disruptive Behavior Disorders (DBD) Market: Competitive Dashboard
14.2 Global Disruptive Behavior Disorders (DBD) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Bionomics
14.3.3 Chelsea Therapeutics
14.3.4 Pfizer
14.3.5 Johnson & Johnson
14.3.6 DURECT
14.3.7 Novartis
14.3.8 McNeil Pharmaceuticals
14.3.9 Sunovion Pharmaceuticals
14.3.10 New River Pharmaceuticals
